Technical Analysis for STX - Shield Therapeutics Plc

Grade Last Price % Change Price Change
D 53.0 1.92% 1.00
STX closed up 1.92 percent on Wednesday, May 12, 2021, on 1.28 times normal volume.
Earnings due: May 17
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Up
Historical STX trend table...

Date Alert Name Type % Chg
Pocket Pivot Bullish Swing Setup 0.00%
Upper Bollinger Band Walk Strength 0.00%
Inside Day Range Contraction 0.00%
Above Upper BB Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Shooting Star Candlestick Bearish 1.92%
Lizard Bearish Bearish Day Trade Setup 1.92%
Pocket Pivot Bullish Swing Setup 1.92%
Doji - Bearish? Reversal 1.92%
Older End-of-Day Signals for STX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Fell Below Upper Bollinger Band 2 days ago
Rose Above Previous Day's High 2 days ago
Up 5% 2 days ago
Up 3% 2 days ago
Up 2% 2 days ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Shield Therapeutics Plc Description

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. The Company's product, Feraccru, is an oral treatment for iron deficiency anemia (IDA) in patients for whom intravenous iron or blood transfusions is needed. It also has a pipeline of over three prescription pharmaceutical assets, including PT20, PT30 and PT40. PT20, which is in Phase II clinical trials, is used as a treatment for hypophosphatemia. PT30, which indicates advanced intravenous (IV) iron formulation, is in pre-clinical stage. Its PT40, which indicates generic IV iron formulation, is in pre-clinical trials. Feraccru, which indicates IDA in chronic kidney disease (CKD) and inflammatory bowel disease (IBD), is in Phase III clinical trials. Its other indications for Feraccru are in Phase II clinical trials.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Health Iron Pharmaceutical Medicine Pipe Clinic Pharmaceuticals Hospital Disease Clinical Trial Blood Pharmaceutical Industry Rtt Phosphate Clinical Research Kidney Disease Chronic Kidney Disease Design Of Experiments Anemia Inflammatory Bowel Disease

Is STX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 153.0
52 Week Low 31.75
Average Volume 1,609,485
200-Day Moving Average 84.23
50-Day Moving Average 42.14
20-Day Moving Average 47.04
10-Day Moving Average 49.12
Average True Range 3.45
ADX 33.02
+DI 34.14
-DI 10.18
Chandelier Exit (Long, 3 ATRs ) 47.04
Chandelier Exit (Short, 3 ATRs ) 52.86
Upper Bollinger Band 52.48
Lower Bollinger Band 41.59
Percent B (%b) 1.05
BandWidth 23.15
MACD Line 2.23
MACD Signal Line 1.67
MACD Histogram 0.5563
Fundamentals Value
Market Cap 62.19 Million
Num Shares 117 Million
EPS 3.60
Price-to-Earnings (P/E) Ratio 14.72
Price-to-Sales 19.50
Price-to-Book 4.04
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 56.00
Resistance 3 (R3) 56.00 55.00 55.50
Resistance 2 (R2) 55.00 54.24 55.00 55.33
Resistance 1 (R1) 54.00 53.76 54.50 54.00 55.17
Pivot Point 53.00 53.00 53.25 53.00 53.00
Support 1 (S1) 52.00 52.24 52.50 52.00 50.83
Support 2 (S2) 51.00 51.76 51.00 50.67
Support 3 (S3) 50.00 51.00 50.50
Support 4 (S4) 50.00